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Abstract
A surveillance study in 1996 identified the USA100 clone (ST5/SCCmecII)–also known as
the “New York/Japan” clone—as the most prevalent MRSA causing infections in 12 New
York City hospitals. Here we update the epidemiology of MRSA in seven of the same hospi-
tals eighteen years later in 2013/14. Most of the current MRSA isolates (78 of 121) belonged
to the MRSA clone USA300 (CC8/SCCmecIV) but the USA100 clone–dominant in the 1996
survey–still remained the second most frequent MRSA (25 of the 121 isolates) causing 32%
of blood stream infections. The USA300 clone was most common in skin and soft tissue
infections (SSTIs) and was associated with 84.5% of SSTIs compared to 5% caused by the
USA100 clone. Our data indicate that by 2013/14, the USA300 clone replaced the New
York/Japan clone as the most frequent cause of MRSA infections in hospitals in Metropoli-
tan New York. In parallel with this shift in the clonal type of MRSA, there was also a striking
change in the types of MRSA infections from 1996 to 2014.
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Introduction
Staphylococcus aureus has remained a leading cause of infections in hospitals and continues to
represent the most frequently identified antibiotic-resistant nosocomial pathogen in many
parts of the world [1]. S. aureus accounted for 12% of all nosocomial infections in the US in
1996, and it still accounts for over 10% of these infections in 2014, in spite of public health con-
trols established in hospitals [2,3]. Moreover, while methicillin-resistant S. aureus (MRSA)
accounted for close to 35% of staphylococcal infections in 1996, this number increased to 60%
of all nosocomial S. aureus infections in more recent years [2–5].
Almost twenty years ago–in 1996 –our laboratory organized a multicenter study to investi-
gate the molecular epidemiology of MRSA in 12 hospitals in Metropolitan New York [2]. At
that time, the most prevalent clone, recovered from 113 of 270 MRSA infections (42%), was
the ‘New York/Japan’ clone (USA100/ST5/SCCmecII), which was also predominant in the
neighboring states of Pennsylvania, New Jersey and Connecticut [6]. Subsequently, the same
clonal type of MRSA was also identified in hospital infections in Japan [7]. In the United States,
this clone has been the predominant MRSA clone in hospitals and healthcare institutions
(HA-MRSA) countrywide over the last fifteen years [8,9].
According to the National Nosocomial Infections Surveillance, the rates of MRSA infection
in hospitals in New York City have been increasing from 619 cases in 1997 (35% of all S. aureus
infections in hospitals) to 3,470 cases in 2004 (60% of all S. aureus infections in hospitals) [10].
In parallel, the frequency of MRSA infections in hospitals due to community-associated MRSA
(CA-MRSA) clones has also increased from 18% in 1997 to 25% in 2004 [9,11].
On the other hand, the New York State Department of Health reported a decrease in the
number of hospital MRSA infections during the past seven years: MRSA infections in colon
surgery decreased from 84 cases in 2008 to 74 in 2013; coronary bypass infections decreased
from 55 in 2008 to 24 in 2013; and central-catheter-associated bloodstream infections in chil-
dren and adults decreased from 73 in 2008 to 20 in 2013. However, the number of central-cath-
eter-associated bloodstream infections in neonatal intensive care units due to MRSA increased
from three in 2008 to ten in 2013 [12,13].
The latest report from the Active Bacterial Core Surveillance Program (ABCSP) described a
reduction in the national incidence of hospital acquired MRSA invasive infections between
2005 and 2011. However, the authors described an increased risk of recurrence among health-
care-associated community-onset infections and a very limited change in the rate of commu-
nity-associated infections [14].
In the present study we report on the clonal types of MRSA isolates recovered from infec-
tions in several of the same hospitals in New York City that participated in the 1996/98
surveillance.
Materials and Methods
The study was reviewed and approved by the Institutional Review Board (IRB) at The Rockefel-
ler University.
Hospital network
The eight hospitals that participated in this study and their location within the greater New
York City area are shown in Fig 1. These hospitals were as follows: VA Hospital (IV) and
Kings County Hospital (XIII) in Brooklyn; Columbia University Medical Center (II) in Man-
hattan; New York-Presbyterian Queens (VI) in Queens; St. Barnabas Hospital (IX) in the
Bronx; Richmond University Medical Center (X) in Staten Island; Stony Brook Health Sciences
Center (XI) in Long Island; and Westchester Medical Center (XII) in Valhalla. Seven of these
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eight hospitals (all except Kings County Hospital) also participated in the previous surveillance
study in 1996.
Source of MRSA isolates
MRSA isolates were obtained from the Pathology Departments of the participating hospitals.
Individual centers were asked to submit single patient MRSA isolates obtained from inpatient
cultures during an extended period from January 2013 to August 2014. The number of speci-
mens provided by each institution was a convenience figure, calculated to be proportional to
the sample size of 1996, the rates of sterile site infections in 2013 and the number of inpatient
beds in each hospital (Table 1). The 121 bacterial isolates were inoculated on BHI, chocolate
slants or blood agar plates for room temperature transportation to the Laboratory of Microbi-
ology and Infectious Diseases at The Rockefeller University on the same day, following the U.S.
Department of Transportation Pipeline and Hazardous Materials Safety Administration
Fig 1. Geographic location of hospitals that participated in the two surveillance studies.Numbers from I to XII represent the 12 hospitals that
collaborated with the Rockefeller University in the 1996 surveillance study and circled in gray are the 8 hospitals that collaborated again in 2013/14. Hospital
XIII was added to the participating hospitals in 2013/14.
doi:10.1371/journal.pone.0156924.g001
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guidelines [15]. All isolates were grown overnight on Mannitol Salt Agar plates (MSA, Difco,
BBL, Becton Dickinson, Franklin Lakes, NJ, USA) and were tested for coagulase agglutination
(Staphaurex, Thermo Fisher Scientific, Lenexa, KS, USA) to confirm species identification.
Antimicrobial susceptibility testing
MRSA antibiograms were performed by either micro-dilution, E-test or disk-diffusion meth-
ods, following the Clinical and Laboratory Standards Institute (CLSI) recommendations [16].
All specimens were tested for susceptibility to a number of antibiotics at the particular hospital
providing the strains. Since not all hospitals tested the same antibiotics, in order to allow com-
parisons, additional tests were performed at the Rockefeller University so all specimens were
tested at least with the following antibiotics: penicillin, oxacillin, ciprofloxacin, clindamycin,
erythromycin, gentamicin, rifampicin, tetracycline, trimethoprim/sulfamethoxazole, linezolid,
nitrofurantoin, chloramphenicol, daptomycin, vancomycin and mupirocin.
Molecular identification: spa typing, MLST, PFGE, SCCmec typing
Molecular characterization of the 121 MRSA isolates was performed initially by spa typing as
described [17] and using the RIDOM web server (http://spaserver.ridom.de/) for assignment of
spa types. The spa server was also used to predict sequence types (ST). MLST was performed as
previously described [18] when the spa server and the bibliography did not provide STs to the
spa types obtained. Assignment of STs was done by DNA amplification and sequencing of
seven housekeeping genes (arcC, aroE, glpF, gmk, pta, tpi, yqiL) using the online MLST data-
base (http://www.mlst.net/). Clonal Complexes were determined for the STs [19].
PFGE was performed to further confirm the relatedness of MRSA isolates belonging to the
same clonal complex. Bacterial DNA was restricted with SmaI enzyme and the resulting frag-
ments were separated by electrophoresis [20]. Band patterns were compared manually follow-
ing guidelines to confirm classification [21,22].
The classification of staphylococcal cassette chromosomemec (SCCmec) carried by the iso-
lates was determined using multiplex PCR, following previous guidelines [23,24]. Ambiguous
results were further tested by amplification of the ccrB gene [25] and comparing the sequences
Table 1. MRSA specimens provided by the participating hospitals.
1996 2013/14
Hospital Location (Fig 1) Neighborhood # MRSA isolates analyzed Beds # MRSA isolates analyzed Beds
Columbia University Medical Center II Manhattan 20 1475 39 1200
Kings County Hospital XIII Brooklyn — — 9 700
VA Hospital IV Brooklyn 15 324 2 340
New York-Presbyterian Queens Center VI Queens 28 487 9 539
St. Barnabas Hospital IX Bronx 18 458 8 417
Richmond University Medical Center X Staten Island 27 638 35 450
Stony Brook Health Sciences Center XI Stony Brook 19 536 10 597
Westchester Medical Center XII Valhalla 17 639 9 635
Total 144 4557 121 4878
Location: Roman numbering identifies the particular hospitals in Fig 1 and also corresponds to the listing in the 1996 surveillance. Some hospitals that
collaborated at that time did not participate in 2013/14, due to closure or association with other institutions.
# MRSA isolates analyzed: isolates of methicillin-resistant S. aureus provided by each hospital.
# Beds: number of inpatient beds per hospital.
doi:10.1371/journal.pone.0156924.t001
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obtained with the online database available at the Laboratory of Molecular Genetics at Instituto
de Tecnologia Quimica e Biologica (ITQB) in Portugal. SCCmec was considered non-typable
(NT) when it was not possible to ascertain a class ofmec complex and/or a type of ccrB.
SCCmec type IV subtyping was also performed by multiplex PCR as previously described [26].
Molecular characterization: detection ofmecA, PVL, and ACME
ThemecA gene, responsible for resistance to oxacillin and other beta-lactam antibiotics and
the lukS and lukF genes (which encode PVL, the Panton-Valentine leukocidin) were identified
by PCR [27,28].
The arginine catabolic mobile element (ACME) element was identified and typed using
primers that target its two main loci (arcA and opp3) in USA300 strain FPR3757 [29] and clas-
sified according to its structure: type I (arc and opp3 operons), type II (arc operon only) and
type III (opp3 operon only)[30].
Results
Of the 12 New York City area hospitals that participated in the original surveillance study in
1996, seven also took part in the study described here. The list of participating hospitals is in
Table 1 and their location is shown in Fig 1. Four of the hospitals that were part of the original
study no longer exist: they closed or merged with other institutions. The molecular epidemiol-
ogy of MRSA in the New York Presbyterian Hospital/Cornell Medical Center will be described
in a separate communication.
The total number of beds in the participating hospitals was 4,878, ranging from 1,200 beds
in hospital II to 340 in hospital IV. A total of 121 MRSA isolates were obtained in the surveil-
lance study. With a median of ten samples per hospital, each center provided MRSA isolates
ranging in number from eight to 39 (Table 1). Most MRSA (26%) was recovered fromMedical
services (Internal Medicine, Neurology, Cardiology, Oncology and Nephrology) and the sec-
ond most frequent source was Pediatrics (25%). Information regarding the service attended at
the time of the sample collection was not available for 12 of the samples: three samples origi-
nating from the VA Hospital in Brooklyn and nine samples from the New York-Presbyterian
Queens Hospital in Flushing. The age of patients ranged from 0 (sample taken at the time of
delivery) to 94 years with a median age of 54 years old; 32% of patients were>60 years old but
the age-group most often involved with MRSA infections was the 0–9 years group (21 cases).
For a single patient the age was not available. Isolates were recovered from a variety of sources:
58 SSTIs (skin and soft tissue infections), 50 blood cultures, four respiratory samples, two sam-
ples from a placental infection (mother and child), one urine sample, one cerebrospinal fluid
sample, and one synovial fluid extraction. No biological source was available for three samples
from the VA Hospital in Brooklyn and for one sample from the Richmond University Medical
Center in Staten Island at the time of the molecular analysis.
Of the 121 isolates characterized 86 (71%) presented a multi-drug resistant (MDR) pheno-
type, i.e, they were resistant to at least three different classes of antibiotics. These MDR isolates
included 20 of the 25 (80%) USA100 strains and 54 of the 78 (69%) USA300 strains. One iso-
late belonging to the USA100 clone was resistant to seven different antibiotics. Isolates belong-
ing to clone USA100 were more frequently than USA300 isolates resistant to quinolones (92%
vs 72%), clindamycin (84% vs 17%), gentamicin (8% vs 0%), rifampicin (8% vs 1%), daptomy-
cin (12% vs 5%), and trimethoprim/sulfamethoxazole (12% vs 4%), while isolates of the
USA300 clone were more often resistant to tetracycline (3% vs 0%) and to mupirocin (13% vs
8%). Both clones showed similar proportion of isolates resistant to erythromycin (92% of
USA100 vs 90% of USA300 isolates). No isolates resistant to linezolid, nitrofurantoin,
MRSA in Hospitals in NYC in 2014
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chloramphenicol or vancomycin were detected. Ten of the 13 isolates showing high resistance
against mupirocin (MIC 1024 μg/ml) belonged to the USA300 clone. The antibiotic resis-
tance patterns of MRSA isolates are shown in Table 2.
The majority of the MRSA isolates (86 of the total of 121) belonged to a variety of commu-
nity-associated MRSA clones, most of these (78 isolates) belonged to the USA300 clone (ST8/
SCCmecIV/PVL±/ACME±). Three were representatives of USA700 (ST72/SCCmecIV/ PVL-/
ACME—); two were USA1100 (ST30/SCCmecIV/PVL+/ACME—); one was USA400 (ST1/
SCCmecIV/PVL+/ACME—); one was USA1000 (ST59/SCCmecIV/PVL—/ACME—); and one
isolate was ST88/SCCmecIVa/PVL+/ACME—.
Molecular characterization of MRSA identified twenty-eight different spa types, which
could be assigned to seven ST types. Of the total of 121 MRSA characterized, 35 belonged to
typical hospital-associated clones: twenty-three of these were representatives of the USA100
(‘New York/Japan’) clone (ST5/SCCmecII/PVL—/ACME—) and two additional isolates shared
the same PFGE/MLST/PVL/ACME profile but had a non-typable SCCmec cassette. There
were three isolates belonging to the USA800 (‘Pediatric’) clone (ST5/SCCmecIV/PVL—/
ACME—); six isolates belonged to the USA500 clone (ST8/SCCmecIV/PVL—/ACME—) and
one isolate had the same PFGE/MLST/PVL/ACME profile as USA500 but carried a non-typ-
able SCCmec cassette.
All but six isolates (72 of 78) belonging to the USA300 clone had the ACME virulence deter-
minant but no strains belonging to the other clones carried ACME. The great majority (74 of
78) of USA300 isolates encoded the PVL toxin; only four isolates belonging to clones other
than USA300 carried these genetic determinants. These were two isolates of the USA1100, one
ST88 isolate and one USA400 isolate. None of the 35 HA-MRSA isolates carried either ACME
or PVL determinants.
Table 2. Antimicrobial resistance profiles of strains characterized in the study.
TOTAL USA100 USA300 Others
n No. R % R n No. R % R n No. R % R n No. R % R
OXA 121 121 100% 25 25 100% 78 78 100% 18 18 100%
CIP 121 90 74% 25 23 92% 78 56 72% 18 11 61%
CLI 121 37 31% 25 21 84% 78 13 17% 18 3 17%
ERY 121 104 86% 25 23 92% 78 70 90% 18 11 61%
GEN 121 3 2% 25 2 8% 78 0 0% 18 1 6%
RIF 121 4 3% 25 2 8% 78 1 1% 18 1 6%
TET 121 5 4% 25 0 0% 78 2 3% 18 3 17%
SXT 121 11 9% 25 3 12% 78 3 4% 18 5 28%
MUP 121 13 11% 25 2 8% 78 10 13% 18 1 6%
DAP 121 7 6% 25 3 12% 78 4 5% 18 0 0%
LZD 121 0 0% 25 0 0% 78 0 0% 18 0 0%
NIT 121 0 0% 25 0 0% 78 0 0% 18 0 0%
VAN 121 0 0% 25 0 0% 78 0 0% 18 0 0%
CHL 121 0 0% 25 0 0% 78 0 0% 18 0 0%
OXA: oxacillin; CIP: ciprofloxacin; CLI: clindamycin; ERY: erythromycin; GEN: gentamicin; RIF: rifampin; TET: tetracycline; SXT: trimethoprim/
sulfamethoxazole; MUP: mupirocin; DAP: daptomycin; LZD: linezolid; NIT: nitrofurantoin; VAN: vancomycin; CHL: chloramphenicol.
No. R: number of isolates resistant to a specific antibiotic; n: number of strains analyzed; %R: percentage of resistant isolates in each group. Highlighted
are those antibiotics to which either USA100 or USA300 are more prone to be resistant.
doi:10.1371/journal.pone.0156924.t002
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The currently major USA300 clone was represented by several spa variants (11 spa types)
with t008 as the most prevalent type (63 of 78 isolates, 80.77%).
The previously dominant MRSA clone USA100 (‘New York/Japan’ clone) was represented
by 25 isolates, 20 of which (80%) had the t002 spa type. The spa types of the remaining clones
are shown in Table 3.
The staphylococcal cassette chromosome (SCCmec) was also characterized: all isolates car-
ried variants of the type IV cassette, except the USA100 (‘New York/Japan’) isolates, which car-
ried the SCCmec-II characteristic of this clone; the cassette was non-typable for two isolates
belonging to the USA100 clone (t002) and one USA500 isolate (t211) (Table 3).
Discussion
The total number of beds in the hospitals collaborating in the 1996 surveillance study was
5,117 as compared to the 4,878 beds in the hospitals participating in the current (2013/14) sur-
veillance. The total number of MRSA isolates characterized in 1996 was 270 and 121 in 2013/
14. In the study described here, the patients were younger than in the previous surveillance:
while 58% of patients were>60 years old in the 1996 study, that age group represented only
32% in the current in 2013/14 study. Medical services are still frequently affected by MRSA
infections. In 1996 this group had 71% of all isolates although in the current surveillance this
number was reduced to 26%. The second most frequently affected service—Pediatrics—had
25% of the MRSA cases in the present study.
Comparison of the results of the surveillance study described here to the surveillance con-
ducted 15 years earlier, in 1996 [2] show several striking differences. In 1996 a single clone,
USA100 (‘New York/Japan’) was responsible for 42% of all MRSA infections in 12 New York
City hospitals [2]. In the study described here, with MRSA isolates collected in 2013/14, a dif-
ferent clone—USA300—was involved with most (64.4%) MRSA infections (Table 4). The
other strains collected in 2013/2014 belonged to three different HA-MRSA clones: 25 were
Table 3. Distribution of MRSA clones and the different spa types and SCCmec types identified in this
study.
MRSA Clones na associated spa types b SCCmec types
USA100 (NY/
Japan)
25 t002 (20), t062 (1), t071 (1), t088 (1), t306 (1), t856 (1) II, NTd (t002)
USA300 78 t008 (62), t024 (1), t051 (1), t068 (2), t121 (3), t211 (3),
t351 (1), t723 (1), t1635 (1), t2229 (1), t3908 (2)
IVa
USA400 1 t128 (1) IVa
USA500 7 t008 (1), t064 (2), t211 (1), t394 (1), t1774 (1), t13975 (1)c IVg, NT (t211)
USA700 3 t126 (1), t901 (1), t1346 (1) IVa (t126), IVh (t901),
NT (t1346)
USA800 3 t002 (3) IVh, IVnste
USA1000 1 t216 (1) IVa
USA1100 2 t665 (2) IVa
ST88 1 t692 (1) IVa
Total: 121
a Number of MRSA isolates belonging to a particular clone
b Numbers in parenthesis represent the number of isolates with a particular spa type
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representatives of the USA100 clone, seven isolates of USA500 and three to the USA800 clone.
The remaining 86 isolates belonged to six community-acquired MRSA lineages: USA300 (78
isolates), USA700 (three isolates), USA1100 (two isolates), USA400 (one isolate), USA1000
(one isolate) and one ST88 isolate.
The change in clonal type of MRSA was also accompanied by a change in the type of infec-
tions. While in 1996 MRSA was mainly recovered from the respiratory tract (44%), most of the
MRSA infections in 2013/14 were skin and soft tissues (SSTIs) (48%). Also, bacteremia/sepsis
has increased from 17.5% of MRSA infections in 1996 to 41.3% in 2013/14. Fig 2 illustrates the
change in the types of lesions and Fig 3 shows the predominant MRSA clones in 1996 and in
2013/14.
Table 4. Representation of MRSA clones USA100, USA300 and other clonal types in New York City area hospitals during the two surveillance
periods.







Total No of MRSA isolates*
1996 2013/14
Hospital Location** No %# No %# No %# No(ǂ) %# No
Columbia Presbyterian Medical Ctr II 5 25 1 2.5 34 87.0 4 (3) 10.2 39
Kings County Hospital XIII — — 3 37.5 2 80.0 3 (2) 37.5 8
VA Hospital IV 9 60 1 33.3 2 66.6 0 — 3
New York-Presbyterian Queens VI 15 53.6 1 11.1 5 55.5 3 (3) 33.3 9
St. Barnabas Hospital IX 5 27.8 2 25.0 5 62.5 1 12.5 8
Richmond University Medical Ctr X 9 33.3 11 31.4 20 57.1 4 (3) 11.4 35
Stony Brook Health Sciences Center XI 14 73.7 5 50.0 3 30.0 2 (2) 20.0 10
Westchester Medical Center XII 8 47.1 1 10.0 7 80.0 1 10.0 9
TOTAL 113 41.9 25 20.5 78 64.7 18 14.7 121
*Total number of MRSA isolates recovered and tested in 2013/14 surveillance
**See Fig 1
# Clonal type in percentage of all MRSA identified in the hospitals
(ǂ) Numbers in parentheses indicate the number of different clonal types of MRSA identified in the particular hospital.
doi:10.1371/journal.pone.0156924.t004
Fig 2. Change in the clinical sources of MRSA from 1996 to 2014. ‘Respiratory tract’: lower respiratory tract (including sputum and bronch-alveolar
lavage) and sinusitis and pleural fluid. ‘Other’: any other biological specimen from which MRSA was isolated at any of the hospitals including the urinary tract,
cerebro-spinal fluid, synovial fluid, placental biopsy and unlisted specimens.
doi:10.1371/journal.pone.0156924.g002
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Fig 3. PFGE profiles of hospital isolates representing the major clonal types of MRSA identified in the 1996 (A) and the 2013/14 study (B). (A)
PFGE of USA100 isolates in 1996 [2]. (B) PFGE of USA300 isolates in 2013/14. Migration on TBE-agarose gel after digestion with SmaI restriction enzyme.
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While the MRSA clone USA300 is known to have a strong association with SSTIs [31,32],
there is no specific association known between the USA100 clone and respiratory infections. A
recent report from the CDC (Emerging Infections Program Healthcare-Associated Infections
and Antimicrobial Use Prevalence Survey Team) concluded that S. aureus (together with Kleb-
siella oxytoca and K. pneumoniae) were currently the main pathogens responsible for respira-
tory tract and skin and soft infections [33].
As to the possible mechanism that has led to the changed clonal types between the current
and the previous (1996) surveillance, we hypothesize that the infection control mechanisms
introduced in the healthcare system may have succeeded in controlling the spread of
HA-MRSA clones like USA100, while the entry and spread of community-associated MRSA
strains in hospitals may be responsible for the increase of SSTIs and secondary bacteremia/sep-
sis [9,34]. Recent reports indicate that the number of invasive MRSA infections decreased in
the United States in 2011 as compared to 2005, but more MRSA infections occurred in the
community than during hospitalization in 2011 [35,36]. The hospital as a source of MRSA
infections seems to have become better controlled, but the frequency of MRSA infections in the
community appears to be increasing. Several other studies have documented the “escape” of
MRSA clones from hospitals to the healthy community and to public transportation [37,38].
New clones circulating in both the community and hospitals also come with a change in
patient demographics, i.e., younger patients presenting with different types of infections and
with an increase in SSTIs and blood infections and decrease in respiratory infections caused by
MRSA [3,39,40].
The change in clonal type of MRSA strains in hospitals between the two studies in 1996 and
2013/14 is also associated with a change in the pattern of antibiotic resistance. In the study per-
formed in 1996, where the USA100 clone was predominant, up to 96% of strains analyzed were
resistant to ciprofloxacin. In 2013/14 only 74% of strains showed this resistance phenotype.
This may be due to the current predominance of strains belonging to the USA300 clone (72%
of them resistant to ciprofloxacin), as resistance to quinolones reached 92% of strains belong-
ing to the USA100 clone. Similarly, resistance to clindamycin affected 88% of strains in 1996,
while only 31% of strains in 2013/14 were resistant to this antibiotic, and 84% of the clindamy-
cin resistant strains belonged to the USA100 clone. In addition, in 1996 it was reported that
58% of the characterized strains were resistant to gentamicin while in 2013/14 only three iso-
lates showed this phenotype.
Following the recommendations of the Infectious Diseases Society of America [41] vanco-
mycin has been the antibiotic of choice against MRSA invasive infections in hospitalized
patients in each of the hospitals participating in this study. All MRSA isolates characterized in
this study were susceptible to this antibiotic. Other therapeutic options such as daptomycin,
clindamycin, rifampin, gentamicin or trimethoprim/sulfamethoxazole have also been used–
alone or in combination–and the high rates of resistance observed in our study to these antibi-
otics underlines the importance of keeping track of the drug resistance mechanisms of MRSA
strains circulating in a hospital–in order to prevent possible treatment failures. It should also
be noted that a number of isolates belonging to the currently predominant MRSA clone
USA300 –also show resistance to mupirocin (see Table 2)–an agent frequently used for decolo-
nization and topical treatment [42].
It is interesting that the SCCmec type IV, common in community-associated MRSA
(CA-MRSA), is also present in some HA-MRSA clones like USA500 or USA800. As many as
USA100 (‘New York/Japan’) was the predominant clone in 1996, and the second most frequent clone in 2013–14. The roman numbers on each strain
indicate the hospital in which they were isolated.
doi:10.1371/journal.pone.0156924.g003
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98 out of the 121 hospital isolates studied here were harboring the type IV SCCmec cassette,
compared to the 23 isolates belonging to USA100 which carried the SCCmec cassette type II.
The smaller size of the type IV cassette has been postulated as an evolutionary advantage for
MRSA clones carrying this cassette [8,9,31].
The virulence factors ACME and PVL are often carried by CA-MRSA strains even when
these clones are recovered in the hospital setting. In our study, ACME was exclusively carried
by USA300 strains while the PVL was present in other CA-MRSA clones as well.
Several factors may have contributed to the shift in the clonal type of MRSA from the “New
York/Japan clone” dominant in the 1996 surveillance to the MRSA clone USA300 most preva-
lent in 2013/14. These factors may include the smaller (type IV) SCCmec cassette carried by
the USA300 clone and also the presence of virulence factors like ACME and PVL in the MRSA
clone USA300, which seems to have emerged as the most prevalent clone both in hospitals and
in the community [11,31,43].
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